Human papillomavirus recombinant vaccine nonavalent (6,11,16,18,31,33,45,52,58) (Shanghai Bovax Biotechnology)

重组人乳头瘤病毒（6/11/16/18/31/33/45/52/58型）九价疫苗（汉逊酵母）（上海博唯）

Report date: 2022/10/17 12:42:20

Base Information

Drug NameHuman papillomavirus recombinant vaccine nonavalent (6,11,16,18,31,33,45,52,58) (Shanghai Bovax Biotechnology)
Drug Alias Name9-valent HPV recombinant vaccine(Shanghai Bovax Biotechnology)Zerun 9-valent Human Papillomarivus (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58)
ClassificationVaccines > Application > Prophylactic vaccineVaccines > Biological material > Viral vaccineVaccines > Vaccine type > Multivalent vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsSquamous Intraepithelial Lesions of the CervixPrecancerous ConditionsNeoplasm Invasiveness +[13] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesShanghai Bovax Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Bovax Biotechnology Co LtdWalvax Biotechnology Co LtdShanghai Zerun Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsSquamous Intraepithelial Lesions of the CervixVulvar NeoplasmsVaginal Neoplasms +[9] 
Inactive IndicationsPrecancerous ConditionsNeoplasm InvasivenessCarcinoma in Situ +[4] 

Other Information

ATC CodeN/A
Related LinksN/A